Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
Nat Med
; 29(9): 2278-2285, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37592104
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nivolumab
/
Melanoma
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Nat Med
Journal subject:
BIOLOGIA MOLECULAR
/
MEDICINA
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Estados Unidos